Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence

@inproceedings{Campbell2009TreatmentSF,
  title={Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence},
  author={Jonathan D. Campbell and Katharine Suzanne Gries and Jonathan H Watanabe and Arliene Ravelo and Roger R Dmochowski and Sean D. Sullivan},
  booktitle={BMC urology},
  year={2009}
}
BackgroundTreatment options for overactive bladder (OAB) with urinary urge incontinence (UUI) refractory to oral antimuscarinics include: botulinum toxin type A (BoNTA), sacral neuromodulation (SNM), and augmentation cystoplasty (AC). A standard treatment success metric that can be used in both clinical and economic evaluations of the above interventions has not emerged. Our objective was to conduct a literature review and synthesis of published measures of treatment success for OAB with UUI… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 22 CITATIONS

Time-to-effect with darifenacin in overactive bladder: a pooled analysis

  • International Urogynecology Journal
  • 2011
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment

  • International journal of applied & basic medical research
  • 2011
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 72 REFERENCES

Behavioral therapies for overactive bladder: making sense of the evidence.

  • Journal of wound, ostomy, and continence nursing : official publication of The Wound, Ostomy and Continence Nurses Society
  • 2008
VIEW 1 EXCERPT

Cost Analysis of Overactive Bladder Treatments for Oral Antimuscarinic Refractory Patients

JH Watanabe, JD Campbell
  • American Urological Association:
  • 2008
VIEW 1 EXCERPT